"Fei Yan No. 1" as a Combined Treatment for COVID-19: An Efficacy and Potential Mechanistic Study
- PMID: 33132913
- PMCID: PMC7580177
- DOI: 10.3389/fphar.2020.581277
"Fei Yan No. 1" as a Combined Treatment for COVID-19: An Efficacy and Potential Mechanistic Study
Abstract
There has been a large global outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), representing a major public health issue. In China, combination therapy, including traditional Chinese medicine (TCM) as a treatment for COVID-19 has been used widely. "Fei Yan No. 1" (QFDYG) is a formula recommended by the Hubei Government to treat COVID-19. A retrospective study of 84 COVID-19 patients from Hubei Provincial Hospital of TCM and Renmin Hospital of Hanchuan was conducted to explore the clinical efficacy of QFDYG combination therapy. TCMSP and YaTCM databases were used to determine the components of all Chinese herbs in QFDYG. Oral bioavailability (OB) ≥ 30% and drug-like (DL) quality ≥ 0.18 were selected as criteria for screening the active compounds identified within the TCMSP database. The targets of active components in QFDYG were determined using the Swiss TargetPrediction (SIB) and Targetnet databases. The STRING database and the Network Analyzer plugin in Cytoscape were used to obtain protein-protein interaction (PPI) network topology parameters and to identify hub targets. Gene Ontology (GO) enrichment was conducted using FunRich version 3.1.3, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment using ClueGO version 2.5.6 software. PPI and compound-pathway (C-T) networks were constructed using Cytoscape 3.6.0. Compared with the control group, combined treatment with QFDYG resulted in a significantly higher rate of patients recovering from symptoms and shorter the time. After 14 days of treatment, QFDYG combined treatment increased the proportion of patients testing negative for SARS-CoV-2 nucleic acid by RT-PCR. Compared with the control group, promoting focal absorption and inflammation as viewed on CT images. GO and KEGG pathway enrichment indicated that QFDYG principally regulated biological processes, such as inflammation, an immune response, and apoptosis. The present study revealed that QFDYG combination therapy offered particular therapeutic advantages, indicating that the theoretical basis for the treatment of COVID-19 by QFDYG may play an antiviral and immune response regulation through multiple components, targets, and pathways, providing reference for the clinical treatment of COVID-19.
Keywords: COVID-19; Fei Yan NO1; SARS-CoV-2; clinical efficacy; network pharmacology.
Copyright © 2020 Ai, Zhou, Li, Wang, Wang, Hu, Tao, Wang, Shen, Xie, Ba, Wu and Yang.
Figures








Similar articles
-
The pharmacological mechanism of Huashi Baidu Formula for the treatment of COVID-19 by combined network pharmacology and molecular docking.Ann Palliat Med. 2021 Apr;10(4):3864-3895. doi: 10.21037/apm-20-1759. Epub 2021 Mar 8. Ann Palliat Med. 2021. PMID: 33691446
-
Identification of phytochemical compounds of Fagopyrum dibotrys and their targets by metabolomics, network pharmacology and molecular docking studies.Heliyon. 2023 Mar;9(3):e14029. doi: 10.1016/j.heliyon.2023.e14029. Epub 2023 Mar 1. Heliyon. 2023. PMID: 36911881 Free PMC article.
-
Network analysis for elucidating the mechanisms of Shenfu injection in preventing and treating COVID-19 combined with heart failure.Comput Biol Med. 2022 Sep;148:105845. doi: 10.1016/j.compbiomed.2022.105845. Epub 2022 Jul 14. Comput Biol Med. 2022. PMID: 35849948 Free PMC article.
-
Potential Treatment of COVID-19 with Traditional Chinese Medicine: What Herbs Can Help Win the Battle with SARS-CoV-2?Engineering (Beijing). 2022 Dec;19:139-152. doi: 10.1016/j.eng.2021.08.020. Epub 2021 Oct 28. Engineering (Beijing). 2022. PMID: 34729244 Free PMC article. Review.
-
Efficacy and mechanisms of traditional Chinese medicine for COVID-19: a systematic review.Chin Med. 2022 Feb 28;17(1):30. doi: 10.1186/s13020-022-00587-7. Chin Med. 2022. PMID: 35227280 Free PMC article. Review.
Cited by
-
In silico analysis of the potential mechanism of a preventive Chinese medicine formula on coronavirus disease 2019.J Ethnopharmacol. 2021 Jul 15;275:114098. doi: 10.1016/j.jep.2021.114098. Epub 2021 Apr 5. J Ethnopharmacol. 2021. PMID: 33831468 Free PMC article.
-
Molecular Mechanism of Naringenin Against High-Glucose-Induced Vascular Smooth Muscle Cells Proliferation and Migration Based on Network Pharmacology and Transcriptomic Analyses.Front Pharmacol. 2022 Jun 9;13:862709. doi: 10.3389/fphar.2022.862709. eCollection 2022. Front Pharmacol. 2022. PMID: 35754483 Free PMC article.
-
Traditional Chinese medicine in COVID-19.Acta Pharm Sin B. 2021 Nov;11(11):3337-3363. doi: 10.1016/j.apsb.2021.09.008. Epub 2021 Sep 20. Acta Pharm Sin B. 2021. PMID: 34567957 Free PMC article. Review.
-
Chromosome-level genome assembly of Amomum tsao-ko provides insights into the biosynthesis of flavor compounds.Hortic Res. 2022 Sep 19;9:uhac211. doi: 10.1093/hr/uhac211. eCollection 2022. Hortic Res. 2022. PMID: 36479578 Free PMC article.
-
Efficacy and safety of chinese herbal medicine for treating mild or moderate COVID-19: A systematic review and meta-analysis of randomized controlled trials and observational studies.Front Pharmacol. 2022 Sep 7;13:988237. doi: 10.3389/fphar.2022.988237. eCollection 2022. Front Pharmacol. 2022. PMID: 36160412 Free PMC article.
References
-
- Ba Y., Wang L., Li W., Zhang X. (2020). Multicenter clinical study on 451 cases of COVID-19 treated with ‘Pneumonia No.1 Formula’. World Chin. Med. 15 (13), 1962–1966. 10.3969/j.issn.1673-7202.2020.13.021 - DOI
LinkOut - more resources
Full Text Sources
Miscellaneous